Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 4/20 | 0.47 |
| ▸ | FBP1 | P09467 | 5/20 | 0.46 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3684057 | 0.93 | PPARA (0.49) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL6828990 | 0.84 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3683043 | 0.81 | PPARA (0.64) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3903999 | 0.80 | PPARA (0.76) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL25167622 | 0.79 | BCHE (0.59) | PPARA | |
| SCHEMBL8210871 | 0.79 | NPSR1 (0.60) | TSHRENPP1 | |
| SCHEMBL6906905 | 0.78 | CA1 (0.50) | CYP3A4ENPP1 | |
| SCHEMBL18289524 | 0.78 | CA1 (0.50) | CYP3A4ENPP1 | |
| SCHEMBL26813621 | 0.78 | CYP1A2 (0.48) | CYP1A2TSHRENPP1 | |
| SCHEMBL3827170 | 0.78 | PPARA (0.54) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | PPARA 2/4885ABCB11 824/4885CYP1A2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.